FIELD: biotechnology.
SUBSTANCE: antibody variants that specifically bind the C3 component of human complement, compositions containing such antibodies, and methods of their use are provided. Also the polynucleotides and vectors encoding antibodies and cells containing them are provided.
EFFECT: invention can be used in the treatment of eye diseases in which complement activation is involved.
31 cl, 6 dwg, 22 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
| METHOD FOR PREPARING ANTIBODY-DRUG CONJUGATE BASED ON ERIBULIN | 2020 |
|
RU2840013C1 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN AND METHODS OF THE USE THEREOF | 2015 |
|
RU2766094C2 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| ST2 ANTIGEN BINDING PROTEIN | 2021 |
|
RU2841164C2 |
